Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 18;6(6):CD008215.
doi: 10.1002/14651858.CD008215.pub3.

Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility

Ivana Rizzuto  1 , Renee F Behrens, Lesley A Smith
Affiliations

Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility

Ivana Rizzuto et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an updated version of the original Cochrane Review published in the Cochrane Library in 2013 (Issue 8) on the risk of ovarian cancer in women using infertility drugs when compared to the general population or to infertile women not treated. The link between fertility drugs and ovarian cancer remains controversial.

Objectives: To evaluate the risk of invasive ovarian cancer and borderline ovarian tumours in women treated with ovarian stimulating drugs for subfertility.

Search methods: The original review included published and unpublished observational studies from 1990 to February 2013. For this update, we extended the searches from February 2013 to November 2018; we evaluated the quality of the included studies and judged the certainty of evidence by using the GRADE approach. We have reported the results in a Summary of findings table to present effect sizes across all outcome types.

Selection criteria: In the original review and in this update, we searched for randomised controlled trials (RCTs) and non-randomised studies and case series including more than 30 participants.

Data collection and analysis: At least two review authors independently conducted eligibility and 'Risk of bias' assessments and extracted data. We grouped studies based on the fertility drug used for two outcomes: borderline ovarian tumours and invasive ovarian cancer. We conducted no meta-analyses due to expected methodological and clinical heterogeneity.

Main results: We included 13 case-control and 24 cohort studies (an additional nine new cohort and two case-control studies), which included a total of 4,684,724 women.Two cohort studies reported an increased incidence of invasive ovarian cancer in exposed subfertile women compared with unexposed women. One reported a standardised incidence ratio (SIR) of 1.19 (95% confidence interval (CI) 0.54 to 2.25) based on 17 cancer cases. The other cohort study reported a hazard ratio (HR) of 1.93 (95% CI 1.18 to 3.18), and this risk was increased in women remaining nulligravid after using clomiphene citrate (HR 2.49, 95% CI 1.30 to 4.78) versus multiparous women (HR 1.52, 95% CI 0.67 to 3.42) (very low-certainty evidence). The slight increase in ovarian cancer risk among women having between one and three cycles of in vitro fertilisation (IVF) was reported, but this was not clinically significant (P = 0.18). There was no increase in risk of invasive ovarian cancer after use of infertility drugs in women with the BRCA mutation according to one cohort and one case-control study. The certainty of evidence as assessed using GRADE was very low.For borderline ovarian tumours, one cohort study reported increased risk in exposed women with an SIR of 3.61 (95% CI 1.45 to 7.44), and this risk was greater after treatment with clomiphene citrate (SIR 7.47, 95% CI 1.54 to 21.83) based on 12 cases. In another cohort study, the risk of a borderline ovarian tumour was increased, with an HR of 4.23 (95% CI 1.25 to 14.33), for subfertile women treated with IVF compared with a non-IVF-treated group with more than one year of follow-up. A large cohort reported increased risk of borderline ovarian tumours, with HR of 2.46 (95% CI 1.20 to 5.04), and this was based on 17 cases. A significant increase in serous borderline ovarian tumours was reported in one cohort study after the use of progesterone for more than four cycles (risk ratio (RR) 2.63, 95% CI 1.04 to 6.64). A case-control study reported increased risk after clomiphene citrate was taken, with an SIR of 2.5 (95% CI 1.3 to 4.5) based on 11 cases, and another reported an increase especially after human menopausal gonadotrophin was taken (odds ratio (OR) 9.38, 95% CI 1.66 to 52.08). Another study estimated an increased risk of borderline ovarian tumour, but this estimation was based on four cases with no control reporting use of fertility drugs. The certainty of evidence as assessed using GRADE was very low.However, although some studies suggested a slight increase in risks of ovarian cancer and borderline ovarian tumour, none provided moderate- or high-certainty evidence, as summarised in the GRADE tables.

Authors' conclusions: Since the last version of this review, only a few new relevant studies have provided additional findings with supporting evidence to suggest that infertility drugs may increase the risk of ovarian cancer slightly in subfertile women treated with infertility drugs when compared to the general population or to subfertile women not treated. The risk is slightly higher in nulliparous than in multiparous women treated with infertility drugs, and for borderline ovarian tumours. However, few studies have been conducted, the number of cancers is very small, and information on the dose or type of fertility drugs used is insufficient.

PubMed Disclaimer

Conflict of interest statement

Ivana Rizzuto: none known. Renee Behrens: none known. Lesley Smith: none known.

Figures

1
1
Identification and selection of studies.
2
2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Analyses include only studies reporting risk of ovarian cancer as an odds ratio (OR).
4
4
Analyses include only studies reporting risk of ovarian cancer as an odds ratio (OR).
1.1
1.1. Analysis
Comparison 1 Infertility drugs vs no infertility drugs, Outcome 1 Invasive ovarian cancer.
1.2
1.2. Analysis
Comparison 1 Infertility drugs vs no infertility drugs, Outcome 2 Borderline ovarian cancer.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Asante 2013 {published and unpublished data}
    1. Asante A, Leonard PH, Weaver AL, Goode EL, Jensen JR, Stewart EA, et al. Fertility drug use and the risk of ovarian tumours in infertile women: a case‐control study. Fertility and Sterility 2013;99(7):2031‐6. - PMC - PubMed
Bjornholt 2015 {published data only}
    1. Bjornholt S, Kruger Kjaer S, Svane Nielsen TS, Jensen A. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population‐based cohort study. Human Reproduction 2015;30(1):222‐31. - PubMed
Brinton 2013 {published data only}
    1. Brinton LA, Trabert B, Shalev V, Lunenfield E, Sella T, Chodick G. In vitro fertilization and risk of breast and gynaecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare services. Fertility and Sterility 2013;99(5):1189‐96. - PMC - PubMed
Calderon‐Margalit 2009 {published and unpublished data}
    1. Calderon‐Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology 2008;169(3):365‐75. - PMC - PubMed
Dor 2002 {published and unpublished data}
    1. Dor J, Lerner‐Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility 2002;77(2):324‐7. - PubMed
Dos Santos Silva 2009 {published and unpublished data}
    1. Dos Santos Silva I, Wark PA, McCormack VA, Mayer D, Overton C, Little V, et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer 2009;100:1824‐31. - PMC - PubMed
Doyle 2002 {published and unpublished data}
    1. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction 2002;17(8):2209‐13. - PubMed
Franceschini 1994 {published and unpublished data}
    1. Franceschini S, Vecchia C, Negri E, Guarneri S, Montella M, Conti E, et al. Fertility drugs and risk of epithelial ovarian cancer in Italy. Human Reproduction 1994;9(9):1673‐5. - PubMed
Gronwald 2015 {published data only}
    1. Gronwald J, Glass K, Rosen B, Karlan B, Tung N, The Hereditary Breast Cancer Clinical Study Group, et al. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA 2 mutation. Fertility and Sterility 2015;105(3):781‐5. - PubMed
Jensen 2009 {published and unpublished data}
    1. Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ 2009;338:1‐8. - PMC - PubMed
Kallen 2011 {published and unpublished data}
    1. Kallen B, Finnstrom O, Lindam A, Nilsson E, Nygren K‐G, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Human Reproduction 2011;26(1):253‐8. - PubMed
Kessous 2016 {published data only}
    1. Kessous K, Davidson E, Meirovitz M, Sergienko R, Sheiner E. The risk of female malignancies after fertility treatments: a cohort study with 25 year follow‐up. Journal of Cancer Research and Clinical Oncology 2016;142:287‐93. - PMC - PubMed
Kurta 2012 {published and unpublished data}
    1. Kurta ML, Moysich KB, Weissfeld JL, Youk AO, Bunker CH, Edwards RP, et al. Use of fertility drugs and risk of ovarian cancer: results from a US‐based case‐control study. Cancer Epidemiology, Biomarkers and Prevention 2012;21(8):1282‐92. - PMC - PubMed
Lerner‐Geva 2003 {published and unpublished data}
    1. Lerner‐Geva L, Geva E, Lessing JB, Chetrit A, Modan B, Amit A. The possible association between in vitro fertilization treatments and cancer development. International Journal of Gynecological Cancer 2003;13:23‐7. - PubMed
Lerner‐Geva 2012 {published and unpublished data}
    1. Lerner‐Geva L, Jaron R, Liraz O, Tzvia B, Shlomo M, Bruno L. Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology 2012;28(10):809‐14. - PubMed
Luke 2015 {published data only}
    1. Luke B, Brown MB, Spector LG, Missmer SA, Leach RE, William M, et al. Cancer in women after assisted reproductive technology. Fertility and Sterility 2015;104(5):1218‐26. - PMC - PubMed
Modan 1998 {published and unpublished data}
    1. Modan B, Ron E, Lerner‐Geva L, Blumstein T, Menczer J, Rabinovici J, et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology 1998;147:1038‐42. - PubMed
Mosgaard 1997 {published and unpublished data}
    1. Mosgaard BJ, Lidegaard BJ, Kjaer SK, Schou G, Anderson AN. Infertility, fertility drugs, and invasive ovarian cancer: a case‐control study. Fertility and Sterility 1997;67(6):1005‐12. - PubMed
Mosgaard 1998 {published and unpublished data}
    1. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Anderson AN. Ovarian stimulation and borderline ovarian tumours: a case‐control study. Fertility and Sterility 1998;70(6):1049‐55. - PubMed
Parazzini 1997 {published and unpublished data}
    1. Parazzini F, Negri E, Vecchia C, Moroni S, Franceschini S, Crosignani PG. Treatment for infertility and risk of invasive epithelial ovarian cancer. Human Reproduction 1997;12(10):2159‐61. - PubMed
Parazzini 1998 {published and unpublished data}
    1. Parazzini F, Negri E, Vecchia C, Moroni S, Polatti A, Chiaffarino F, et al. Treatment for fertility and risk of ovarian tumours of borderline malignancy. Human Reproduction 1998;68:226‐8. - PubMed
Parazzini 2001 {published and unpublished data}
    1. Parazzini F, Pelucchi C, Negri E, Franceschini S, Talamini R, Montella M, et al. Use of fertility drugs and risk of ovarian cancer. Human Reproduction 2001;16(7):1372‐5. - PubMed
Perri 2015 {published data only}
    1. Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben‐Baruch G, et al. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA 1 or BRCA 2 mutation carriers. Fertility and Sterility 2015;103(5):1305‐12. - PubMed
Potashnik 1999 {published and unpublished data}
    1. Potashnik G, Lerner‐Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility 1999;71(5):853‐9. - PubMed
Reigstad 2015 {published data only}
    1. Reigstad MM, Larsen IK, Myklebust TA, Robsahm TE, Oldereid NB, Omland AK, et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction 2015;30(8):1952‐63. - PMC - PubMed
Reigstad 2017 {published data only}
    1. Reigstad MM, Storeng R, Myklebust TA, Oldereid NB, Omland AK, Robsahm TE, et al. Cancer risk in women treated with fertility drugs according to parity status ‐ A registry‐based cohort study. Cancer Epidemiology, Biomarkers & Prevention 2017;26(6):953‐62. - PMC - PubMed
Rossing 1994 {published and unpublished data}
    1. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumours in a cohort of infertile women. New England Journal of Medicine 1994;331(12):771‐6. - PubMed
Rossing 2004 {published and unpublished data}
    1. Rossing MA, Tang Mei‐Tzu C, Flagg EW, Weiss LK, Wicklund KG. A case‐control study of ovarian cancer in relation to infertility and the use of ovulation‐inducing drugs. American Journal of Epidemiology 2004;160(11):1070‐8. - PubMed
Sanner 2009 {published and unpublished data}
    1. Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, Bergh T, et al. Ovarian epithelial neoplasia after hormonal infertility treatment: long‐term follow‐up of a historical cohort in Sweden. Fertility and Sterility 2009;91:1152‐8. - PubMed
Shushan 1996 {published and unpublished data}
    1. Shushan A, Paltiel O, Isovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertility and Sterility 1996;65(1):13‐8. - PubMed
Stewart 2013 {published data only}
    1. Stewart LM, Holman CDJ, Aboagye‐Sarfo P, Finn JC, Preen DB, Hart R. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecologic Oncology 2013;128:260‐4. - PubMed
    1. Stewart LM, Holman CJ, Finn JC, Preen DB, Hart R. In vitro fertilization is associated with an increased risk of borderline ovarian tumours. Gynecologic Oncology 2013;129:372‐6. - PubMed
Stewart 2013a {published data only}
    1. Stewart L.M, Holman C. D'Arcy J, J. C. Finn, D.B. Preen, R. Hart. In‐vitro fertilization is associated with an increased risk of borderline ovarian tumours. Gynaecol Oncology 2013;129(2):372‐376. - PubMed
Trabert 2013 {published data only}
    1. Trabert B, lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa A, et al. Ovulation‐inducing drugs and ovarian cancer risk: results from an extended follow‐up of a large US infertility cohort. Fertility and Sterility 2013;100(6):1‐12. - PMC - PubMed
Van Leeuwen 2011 {published data only}
    1. Leeuwen FE, Klip H, Mooij TM, Swaluw AMG, Lambalk CB, Kortman M, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Human Reproduction 2011;26(12):3456‐65. - PMC - PubMed
Venn 1995 {published data only}
    1. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995;346:995‐1000. - PubMed
Venn 1999 {published and unpublished data}
    1. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of infertility drugs with in‐vitro fertilisation. Lancet 1999;354:1586‐90. - PubMed
Yli‐Kuha 2012 {published and unpublished data}
    1. Yli‐Kuha A‐N, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction 2012;27(4):1149‐55. - PubMed

References to studies excluded from this review

Adami 1994 {published data only}
    1. Adami H‐O, Hsieh C‐C, Lambe M, Trichopoulos D, Leon D, Persson I, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344:1250‐4. - PubMed
Adelson 1993 {published data only}
    1. Adelson MD, Reece MT. Effects of gonadotropin‐releasing hormone analogues on ovarian epithelial tumours. Clinical Obstetrics & Gynaecology 1993;36(3):690‐700. - PubMed
Albrektsen 1996 {published data only}
    1. Albrektsen G, Heuch I, Kvale G. Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes and Control 1996;7(4):421‐7. - PubMed
Allaway 2017 {published data only}
    1. Allaway HCM, Chizen DR, Adams GP, Pierson RA. Effects of a single 20 mg dose of letrozole on ovarian function post dominant follicle selection: an exploratory randomized controlled trial. Journal of Ovarian Research 2017;10(6):1‐11. - PMC - PubMed
Al‐Shawaf 2005 {published data only}
    1. Al‐Shawaf T, Zosmer A, Dirnfeld M, Grudzinskas G. Safety of drugs used in assisted reproduction techniques. Drug Safety 2005;28(6):513‐28. - PubMed
Althuis 2005 {published data only}
    1. Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology 2005;161(7):607‐15. - PubMed
Anderson 1996 {published data only}
    1. Anderson SM, Dimitrievich E. Ovulation induction for infertility: is it safe or not?. South Dakota Journal of Medicine 1996;49(11):419‐21. - PubMed
Artini 1997 {published data only}
    1. Artini PG, Fasciani A, Cela V, Battaglia C, Micheroux AA, D'Ambrogio G, et al. Fertility drugs and ovarian cancer. Gynecological Endocrinology 1997;11(1):59‐68. - PubMed
Attia 2006 {published data only}
    1. Attia A. EBM in action: does ovulation induction increase the risk of ovarian cancer?. Middle East Fertility Society Journal 2006;11(2):135‐9.
Ayhan 2004 {published data only}
    1. Ayhan A, Salman MC, Celik H, Dursun P, Ozyuncu O, Gultekin M. Association between fertility drugs and gynaecologic cancers, breast cancer, and childhood cancers. Acta Obstetricia et Gynecologica Scandinavica 2004;83:1104‐11. - PubMed
Badawy 2009 {published data only}
    1. Badawy A, Abdel Aal I, Abulatta M. Clomiphene or anastrozole for ovulation for ovulation induction in women with polycystic ovary syndrome? A prospective controlled trial. Fertility and Sterility 2009;92:860‐3. - PubMed
Balasch 1994 {published and unpublished data}
    1. Balasch J, Penarrubia J, Marquez M, Mirkin SR, Carmona F, Barri PN, et al. Ovulation side and ovarian cancer. Gynecological Endocrinology Journal 1994;8(1):51‐4. - PubMed
Bandera 2005 {published data only}
    1. Bandera C. Advances in the understanding of risk factors for ovarian cancer. Journal of Reproductive Medicine 2005;50:399‐406. - PubMed
Bayar 2006 {published data only}
    1. Bayar U, Demirtas E, Usubütün A, Basaran M, Esinler I, Yarali H. Ovarian adenomyoma following gonadotrophin treatment for infertility. Reproductive Biomedicine Online 2006;13(5):676‐9. - PubMed
Bose 2008 {published data only}
    1. Bose CK. Clomiphene may not cause neoplasia in the ovary: an animal study on ovarian morphology, biochemistry and histochemistry. Journal Turkish‐German Gynecological Association 2008;9(3):158‐63.
Brekelmans 2003 {published data only}
    1. Brekelmans CTM. Risk factors and risk reduction of breast and ovarian cancer. Current Opinion in Obstetrics and Gynecology 2003;15:63‐8. - PubMed
Brinton 1996 {published data only (unpublished sought but not used)}
    1. Brinton LA. Hormones and risk of cancers of the breast and ovary. Cancer Causes Control 1996;7(6):569‐71. - PubMed
Brinton 1997 {published data only (unpublished sought but not used)}
    1. Brinton LA, Gridley G, Persson I, Baron J, Berqqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. American Journal of Obstetrics and Gynecology 1997;176:572‐9. - PubMed
Brinton 2007 {published data only (unpublished sought but not used)}
    1. Brinton L. Long‐term effects of ovulation‐stimulating drugs on cancer risk. Reproductive Biomedicine Online 2007;15(1):38‐44. - PubMed
Brinton 2012 {published and unpublished data}
    1. Brinton LA, Sahasrabuddhe VV, Scoccia B. Fertility drugs and the risk of breast and gynaecologic cancers. Seminars in Reproductive Medicine 2012;30:131‐45. - PMC - PubMed
Bristow 1996 {published data only}
    1. Bristow RE, Karlan BY. The risk of ovarian cancer after treatment for infertility. Current Opinion in Obstetrics and Gynaecology 1996;8:32‐7. - PubMed
Bristow 1996 {published and unpublished data}
    1. Bristow RE, Karlan B. Ovulation induction, infertility, and ovarian cancer risk. Fertility and Sterility 1996;66(4):499‐507. - PubMed
Burger 2004 {published and unpublished data}
    1. Burger CW, Klip H, Leeuwen FE. In vitro fertilization, ovulation induction and the risk of cancer. CME Journal of Gynaecologic Oncology 2004;9:256‐63.
Cetin 2008 {published and unpublished data}
    1. Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor ‐ A review. Placenta 2008;29:169‐77. - PubMed
Chene 2009 {published and unpublished data}
    1. Chene G, Penault‐Llorca F, Bouedec G, Mishellany F, Dauplat MM, Jaffeux P. Ovarian epithelial dysplasia after ovulation induction: time and dose effects. Human Reproduction 2009;24(1):132‐8. - PubMed
Clinton 1997 {published and unpublished data}
    1. Clinton GM, Hua W. Estrogen action in human ovarian cancer. Critical Reviews in Oncology Hematology 1997;25(1):1‐9. - PubMed
Cohen 1993 {published and unpublished data}
    1. Cohen J. Fertility drugs and ovarian cancer. Fertility and Sterility 1993;60(3):406‐8. - PubMed
Cramer 1998 {published and unpublished data}
    1. Cramer DW, Harlow BL, Titus‐Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over‐the‐counter analgesics and risk of ovarian cancer. Lancet 1998;351:104‐7. - PubMed
Crosbie 2005 {published data only (unpublished sought but not used)}
    1. Crosbie E, Menon U. Epithelial ovarian cancer and induction of ovulation. Reviews in Gynaecological Practice 2005;5:131‐8.
Croughan‐Minihane 2001 {unpublished data only}
    1. Croughan‐Minihane M, Camarano L, Feigenbaum S, Adamson NGD, Cadieux M. The risk of ovarian cancer associated with infertility and infertility treatments. Fertility and Sterility 2001;76:S68.
Cusido 2007 {published data only (unpublished sought but not used)}
    1. Cusido M, Fabregas R, Pere Barris S, Escayola C, Nolsac Barr P. Ovulation induction treatment and risk of borderline ovarian tumours. Gynaecological Endocrinology 2007;23(7):373‐6. - PubMed
Demirol 2006 {published data only}
    1. Demirol NA, Guven S, Gurgan T. Ovulation induction agents and cancer. Journal of the Turkish German Gynecological Association 2006;7(2):139‐45.
Devesa 2010 {published data only}
    1. Devesa M, Barri PN, Coroleu B. Assisted reproductive technology and ovarian cancer. Minerva Endocrinologica 2010;35(4):247‐57. - PubMed
Dos Santos 2002 {published and unpublished data}
    1. Dos Santos Silva J, Maclean AB, Mayer D, Hardiman PJ, Lieberman G, Nieto JJ, et al. Does ovarian stimulation increase the risk of ovarian cancer?. Reproductive Medicine Review 2002;11(1):57‐66.
Duckitt 1998 {published data only}
    1. Duckitt K, Templeton A. Cancer in women with infertility. Current Opinion of Obstetrics and Gynaecology 1998;10(3):199‐203. - PubMed
Duska 1996 {published and unpublished data}
    1. Duska L, Wallach EE. Infertility, ovulation induction, and epithelial ovarian cancer. Postgraduate Obstetrics & Gynaecology 1996;16:1‐6.
Franceschini 1991 {published data only (unpublished sought but not used)}
    1. Franceschini S, Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F. Pooled analysis of 3 European case‐control studies of ovarian cancer: II. Age at menarche and at menopause. International Journal of Cancer 1991;49:57‐60. - PubMed
Franco 2000 {published data only}
    1. Franco C, Coppola S, Prosperi Porta R, Patella A. Ovulation induction and risk of ovarian cancer [Induzione dell'ovulazione e rischio di neoplasie ovariche]. Minerva Ginecologica 2000;52:103‐9. - PubMed
Gadducci 2004 {published and unpublished data}
    1. Gaducci A, Gargini A, Palla E, Genazzani AR. Reproductive variables, fertility drugs and epithelial ovarian tumour risk. CME Journal of Gynaecologic Oncology 2004;9:245‐52.
Gadducci 2013 {published and unpublished data}
    1. Gadducci A, Guerrieri ME, Genazzani AR. Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynaecological Endocrinology 2013;29(1):30‐5. - PubMed
Genc 2011 {published and unpublished data}
    1. Genc G, Yilmaz N, Vygur D, Dogan M, Mollamahmutogli L. The effect of intrafollicular IGF 1 and IGFBP3 on IVF outcome in patients using different gonadotropins: a prospective study. Journal of Assisted Reproduction and Genetics 2011;28:405‐10. - PMC - PubMed
Glud 1998 {published data only (unpublished sought but not used)}
    1. Glud E, Kjaer SK, Troisi R, Brinton LA. Fertility drugs and ovarian cancer. Epidemiologic Reviews 1998;20(2):237‐57. - PubMed
Goldberg 1992 {published data only}
    1. Goldberg G, Runowicz CD. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation ‐ Is there a link?. American Journal of Obstetrics and Gynecology 1992;166:853‐4. - PubMed
Goodman 2001 {published data only}
    1. Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, et al. Case‐control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiology Biomarkers and Prevention 2001;10:209‐16. - PubMed
Goshen 1998 {published and unpublished data}
    1. Goshen R, Wessman A, Shoham Z. Epithelial ovarian cancer, infertility and induction of ovulation: possible pathogenesis and updated concepts. Baillieres Clinical Obstetrics and Gynaecology 1998;12(4):581‐91. - PubMed
Gwinn 1990 {published and unpublished data}
    1. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. Journal of Clinical Epidemiology 1990;43(6):559‐68. - PubMed
Hankinson 1995 {published data only (unpublished sought but not used)}
    1. Hankinson S, Colditz G, Hunter DJ, Willett WC, Stampfer MJ, Rosner B. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995;76:284‐90. - PubMed
Harris 1992 {published data only (unpublished sought but not used)}
    1. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case‐control studies. III. Epithelial tumours of low malignant potential in white women. Collaborative Ovarian Cancer Group. American Journal of Epidemiology 1992;136(10):1204‐11. - PubMed
He 2012 {published data only}
    1. He F, Gan X‐L, Hu L‐N. Ovulation induction and risk of ovarian cancer: a systematic review. Chinese Journal of Evidence‐Based Medicine 2012;12(9):1129‐34.
Helzlsouer 1995 {published and unpublished data}
    1. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274:1926‐30. - PubMed
Horn‐Ross 1992 {published data only}
    1. Horn‐Ross P, Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case‐control studies. VI. Nonepithelial cancers among adults. Collaborative Ovarian Cancer Group. Epidemiology 1992;3:490‐5. - PubMed
Jensen 2007 {published data only (unpublished sought but not used)}
    1. Jensen A, Sharif H, Svare E, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiology of Biomarkers and Prevention 2007;16(7):1400‐7. - PubMed
Jensen 2008 {published data only}
    1. Jensen A, Sharif H, Olsen JH, Kjaer SK. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology 2008;168(1):49‐57. - PubMed
Kashyap 2003 {published data only (unpublished sought but not used)}
    1. Kashyap S, Davis OK. Ovarian cancer and fertility medications: a critical appraisal. Seminars in Reproductive Medicine 2003;21(1):65‐71. - PubMed
Kaufman 1995 {published data only}
    1. Kaufman S, Spirtas R, Alexander NJ. Do fertility drugs cause ovarian tumours?. Journal of Women's Health 1995;4(3):247‐59.
Kelly 2003 {published data only}
    1. Kelly AM, Buckett WM, William M, Tan Seang L. Effect of repeated assisted reproductive technology on ovarian response. Current Opinion in Obstetrics and Gynecology 2003;15:219‐24. - PubMed
King 1994 {published data only (unpublished sought but not used)}
    1. King TM. Ovarian cancer and fertility drugs. The Cancer Bulletin 1994;46(2):181‐4.
Klip 2000 {published data only}
    1. Klip H, Burger CW, Kenemans P, Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes and Control 2000;11(4):319‐44. - PubMed
Klip 2001 {published and unpublished data}
    1. Klip H, Burger CW, Kraker J, Leeuwen FE, OMEGA Project Group. Risk of cancer in the offspring of women who underwent ovarian stimulation for IVF. Human Reproduction 2001;16(11):2451‐8. - PubMed
Konishi 1999 {published and unpublished data}
    1. Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology 1999;57(2):45‐8. - PubMed
Kristiansson 2007 {published and unpublished data}
    1. Kristiansson P, Bjor O, Wramsby H. Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction 2007;22(2):421‐6. - PubMed
Kurian 2004 {published data only}
    1. Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynaecologic Oncology 2005;96:520‐30. - PubMed
Land 1993 {published data only}
    1. Land JA. Ovulation, ovulation induction and ovarian carcinoma. Bailliere's Clinical Obstetrics and Gynaecology 1993;7(2):455‐71. - PubMed
La Vecchia C 2011 {published and unpublished data}
    1. Vecchia C. Infertility, ovulation, induced ovulation and female cancers. European Journal of Cancer Prevention 2011;20(3):147‐9. - PubMed
Lerner‐Geva 2004 {published data only}
    1. Lerner‐Geva L. The possible association between infertility, ovulation induction treatments and the incidence of cancer. CME Journal of Gynecologic Oncology 2004;9:236‐44.
Lerner‐Geva 2006 {published and unpublished data}
    1. Lerner‐Geva L, Keinan‐Boker L, Blumstein T, Boyko V, Olmar L, Mashiach S, et al. Infertility, ovulation induction treatments and the incidence of breast cancer: a historical prospective cohort of Israeli women. Breast Cancer Research and Treatment 2006;100:201‐12. - PubMed
Lerner‐Geva 2010 {published and unpublished data}
    1. Lerner‐Geva L, Rabinovici J, Lunenfeld B. Ovarian stimulation: is there a long‐term risk for ovarian, breast and endometrial cancer?. Women's Health (London England) 2010;6(6):831‐9. - PubMed
Li 2013 {published and unpublished data}
    1. Li LL, Zhou J, Qian XJ, Chen YD. Meta‐analysis on the possible association between in vitro fertilization and cancer risk. International Journal of Gynecological Cancer 2013;23:16‐24. - PubMed
Lopes 1993 {published data only}
    1. Lopes P, Mensier A. Ovarian cancer and assisted reproductive technology. European Journal of Obstetrics and Gynecology and Reproductive Biology 1993;51:171‐3. - PubMed
Mandai 2007 {published and unpublished data}
    1. Mandai M, Konishi I, Kuroda H, Fujii S. LH/hCG action and development of ovarian cancer ‐ A short review on biological and clinical/epidemiological aspects. Molecular and Cellular Endocrinology 2007;269:61‐4. - PubMed
McGuire 2004 {published and unpublished data}
    1. McGuire V, Felberg A, Mills M, Ostrow KL, Dicioccio R, John EM, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and non carriers of BRCA 1 gene mutations. American Journal of Epidemiology 2004;160(7):613‐8. - PubMed
McSorley 2009 {published data only}
    1. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, et al. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. International Journal Cancer 2009;125(3):674‐9. - PMC - PubMed
Mendola 2013 {published data only}
    1. Mendola P. Epithelial ovarian tumors and fertility drugs ‐ Are we asking the right questions?. Fertility and Sterility 2013;99(7):1853‐4. - PMC - PubMed
Menon 2009 {published and unpublished data}
    1. Menon U, Gentry‐Maraj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). Lancet Oncology 2009;10(4):327‐34. - PubMed
Miao 2006 {published and unpublished data}
    1. Miao Q, Kong BH. A case‐control study on etiology of epithelial ovarian cancer in Shandong Province. Al Zheng 2006;25(7):871‐5. - PubMed
Modugno 2001 {published and unpublished data}
    1. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. American Journal of Epidemiology 2001;11:568‐74. - PubMed
Negri 1991 {published data only}
    1. Negri E, Franceschini S, Tzonou A, Booth M, Vecchia C, Parazzini F, et al. Pooled analysis of 3 European case‐control studies: I. Reproductive factors and risk of epithelial ovarian cancer. International Journal of Cancer 1991;49:50‐6. - PubMed
Ness 2000 {published data only}
    1. Ness RB, Grisso JA, Klapper J, Schlesselman J, Silberzweig S, Vergona R, SHARE Study Group, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives: steroid hormones and reproductions. American Journal of Epidemiology 2000;152(3):233‐41. - PubMed
Ness 2003 {published and unpublished data}
    1. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case‐control studies. American Journal of Epidemiology 2002;155:217‐24. - PubMed
Ness 2011 {published and unpublished data}
    1. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception methods, beyond oral oral contraceptives and tubal ligation, and risk of ovarian cancer. Annals of Epidemiology 2011;21:188‐96. - PMC - PubMed
Nieto 2001 {published and unpublished data}
    1. Nieto JJ, Crow J, Sundaresan M, Constantinovici N, Perrett CW, MacLean AB, et al. Ovarian epithelial dysplasia in relation to ovulation induction and nulliparity. Gynecologic Oncology 2001;82:344‐9. - PubMed
Oktay 2010 {published and unpublished data}
    1. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA 1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. Journal of Clinical Oncology 2010;28(2):240‐4. - PMC - PubMed
Ozcan 2009 {published and unpublished data}
    1. Ozcan Z, Celik H, Gurates B, Ozercan HI, Hanay F, Nalbant M, et al. Effects of ovulation induction agents on ovarian surface epithelial in rats. Reproductive Biomedicine Online 2009;19(3):314‐8. - PubMed
Ozdemir 2005 {published and unpublished data}
    1. Ozdemir I, Ustundag N, Guven A, Duran B, Dermici F. Effect of clomiphene citrate on ovarian, endometrial, and cervical histologies in a rat model. Gynecologic and Obstetric Investigation 2005;60:181‐5. - PubMed
Parazzini 2004 {published and unpublished data}
    1. Parazzini F, Chiaffarino F, Negri E, Surace M, Benzi G, Franceschini S, et al. Risk factors for different histological types of ovarian cancer. International Journal of Gynecologic Cancer 2004;14:431‐6. - PubMed
Paulson 1996 {published and unpublished data}
    1. Paulson RJ. Fertility drugs and ovarian epithelial cancer: is there a link?. Journal of Assisted Reproduction and Genetics 1996;13(10):751‐6. - PubMed
Persson 1995 {published data only}
    1. Persson I, Janson PO. Ovarian neoplasms. Protective or hazardous effects of sterilization, hysterectomy and hormonal infertility therapy?. Lakartidningen 1995;92(5):371‐4. - PubMed
Purdie 1995 {published data only}
    1. Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case‐control study. International Journal of Cancer 1995;62:678‐84. - PubMed
Riman 1998 {published and unpublished data}
    1. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clinical Endocrinology 1998;49:695‐707. - PubMed
Riman 2002 {published and unpublished data}
    1. Riman T, Dickman PW, Nilsson S, Correira N, Nordlinder H, Magnusson CM. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case‐control study. American Journal of Epidemiology 2002;156(4):363‐73. - PubMed
Rish 1996 {published and unpublished data}
    1. Rish HA, Marrett LD, Jain M, Howe G. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case‐control study. American Journal of Epidemiology 1996;144(4):363‐72. - PubMed
Rodriguez 1998 {published and unpublished data}
    1. Rodriguez C, Tatham LM, Calle EE, Thun MJ, Jacobs EJ, Health CW. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes and Control 1998;9:645‐51. - PubMed
Ron 1995 {published and unpublished data}
    1. Ron E, Lunenfeld B. A review of infertility and its treatment in the etiology of female reproductive and other cancers. Journal of Women's Health 1995;4(3):261‐72.
Rosemberg 1994 {published and unpublished data}
    1. Rosemberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL, Strom BL, et al. A case‐control study of oral contraceptive use and invasive epithelial ovarian cancer. American Journal of Epidemiology 1994;139(7):654‐61. - PubMed
Rosen 1997 {published and unpublished data}
    1. Rosen B, Irvine J, Ritvo P, Shapiro H, Stewart D, Reynolds K, et al. The feasibility of assessing women's perceptions of the risks and benefits of fertility drug therapy in relation to ovarian cancer risk. Fertility and Sterility 1997;68(1):90‐4. - PubMed
Rosenblatt 1993 {published and unpublished data}
    1. Rosenblatt KA, Thomas DB, WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lactation and the risk of epithelial ovarian cancer. International Journal of Epidemiology 1993;22(2):192‐7. - PubMed
Rossing 1996 {published and unpublished data}
    1. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort of infertile women. Gynecologic Oncology 1996;60:3‐7. - PubMed
Schildkraut 1996 {published and unpublished data}
    1. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstetrics and Gynecology 1996;88:554‐9. - PubMed
Shoham 1994 {published data only}
    1. Shoham Z. Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today?. Fertility and Sterility 1994;62(3):433‐48. - PubMed
Siristatidis 2013 {published data only}
    1. Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer. A systematic review and metananalysis. Human Reproduction Update 2013;19(2):105‐23. - PubMed
Smith 2001 {published data only}
    1. Smith JA. The controversial association of the treatment of infertility with fertility agents and development of ovarian cancer: what should patients be told?. Oncology Spectrums 2001;2(6):428‐31.
So 2008 {published and unpublished data}
    1. So W‐K, Cheng J‐C, Poon S‐L, Leung PCK. Gonadotropin‐releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS Journal 2008;275:5496‐511. - PubMed
Soegaard 2007 {published and unpublished data}
    1. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, et al. Different risk factor profiles for mucinous and non mucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiology Biomarkers Prevention 2007;16(6):1160‐6. - PubMed
Spirtas 1993 {published and unpublished data}
    1. Spirtas R, Kaufman SC, Alexander NJ. Fertility drugs and ovarian cancer: red alert or red herring?. Fertility and Sterility 1983;59(2):291‐3. - PubMed
Stein 1997 {published and unpublished data}
    1. Stein DE, Santoro N. Infertility, gonadotropins, and ovarian cancer. Controversies in Infertility Management 1997;8(2):289‐303.
Tarlatzis 1995 {published and unpublished data}
    1. Tarlatzis BC, Grimbizis G, Bontis J, Mantalenakis S. Ovarian stimulation and ovarian tumours: a critical reappraisal. Human Reproduction Update 1995;1(3):284‐301. - PubMed
Trifonov 2000 {published and unpublished data}
    1. Trifonov I, Todorova M, Uzunova ZH. Stimulation of ovulation and ovarian cancer. Literature. Akush Ginekol (Sofiia) 2000;40(4):39‐41. - PubMed
Unkila‐Kallio 1997 {published and unpublished data}
    1. Unkila‐Kallio L, Leminen A, Tiitnen A, Lehtovirta P, Wahlstrom T, Ylikorkala O. Malignant tumours of the ovary or the breast in association with infertility: a report of thirteen cases. Acta Obstetricia et Gynecologica Scandinavica 1997;76:177‐81. - PubMed
Unkila‐Kallio 2000 {published and unpublished data}
    1. Unkila‐Kallio L, Tiitinen A, Wahlstrom T, Lehtovirta P, Leminen A. Reproductive features in women developing ovarian granulosa cell tumour at a fertile age. Human Reproduction 2000;15(3):589‐93. - PubMed
Venn 1997 {published and unpublished data}
    1. Venn AJ, Healy DL. Fertility drugs and cancer. Reproductive Medicine Review 1997;6(3):185‐98.
Venn 2001 {published data only (unpublished sought but not used)}
    1. Venn A, Hemminki E, Watson L, Bruinsma F, Healy D. Mortality in a cohort of IVF patients. Human Reproduction 2001;16(12):2691‐6. - PubMed
Venn 2003 {published data only (unpublished sought but not used)}
    1. Venn A, Healy D, McLachlan R. Cancer risks associated with the diagnosis of infertility. Best Practice & Research Clinical Obstetrics & Gynaecology 2003;17(2):343‐67. - PubMed
Vlahos 2010 {published and unpublished data}
    1. Vlahos N, Economopoulos KP, Creatsas G. Fertility drugs and ovarian cancer risk: a critical review of the literature. Annuals of the New York Academy Sciences 2010;1205:214‐9. - PubMed
Wakeley 2000 {published and unpublished data}
    1. Wakeley KE, Grendys EC. Reproductive technologies and risk of ovarian cancer. Current Opinion of Obstetrics and Gynecology 2000;12:43‐7. - PubMed
Wang 2017 {published data only}
    1. Wang R, Kim BV, Wely M, Johnson NP, Costello MF, Zhang H, et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta‐analysis. BMJ 2017;356:1‐10. - PMC - PubMed
Whittemore 1994 {published data only (unpublished sought but not used)}
    1. Whittemore AS. The risk of ovarian cancer after treatment for infertility. New England Journal of Medicine 1994;331(12):805‐6. - PubMed
Willemsen 1993 {published data only (unpublished sought but not used)}
    1. Willemsen W, Kruitwagen R, Bastiaans B, Hanselaar T, Rolland R. Ovarian stimulation and granulosa‐cell tumour. Lancet 1993;341:986‐8. - PubMed
Zarchi 2013 {published data only}
    1. Zarchi MK, Rouhi M, Abdolahi AH, Hekmatimoghaddam S. The effect of assisted reproductive technologies on gynaecological cancer: report of our experiences and literature review. International Journal of Biomedical Science 2013;9(3):129‐34. - PMC - PubMed
Zreik 2008 {published data only}
    1. Zreik TG, Ayoub CM, Hannoun A, Karam CJ, Munkarah AR. Fertility drugs and risk of ovarian cancer: dispelling the myth. Current Opinion in Obstetrics and Gynecology 2008;20:313‐9. - PubMed

Additional references

Balasch 1993
    1. Balasch J, Barri PN. Follicular stimulation and ovarian cancer?. Human Reproduction 1993;8:990‐6. - PubMed
Biskind 1944
    1. Biskind MS, Biskind GS. Development of tumours in the rat ovary after transplantation into the spleen. Proceedings of the Society for Experimental Biology and Medicine 1944;55:176‐9.
Boivin 2007
    1. Boivin J, Bunting L, Collins J, Nygren KG. International estimates of infertility prevalence and treatment‐seeking: potential need and demand for infertility medical care. Human Reproduction 2007;22(6):1506‐12. - PubMed
Booth 1989
    1. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case control study. British Journal of Cancer 1989;60:592‐8. - PMC - PubMed
Brinton 2005
    1. Brinton L, Moghiss K, Scoccia B, Westhoff C, Lamb E. Ovulation induction and cancer risk. Fertility and Sterility 2005;83(2):261‐74. - PubMed
Brinton 1989
    1. Brinton LA, Melton LJ, Malkasian GD Jr, Bond A, Hoover R. Cancer risk after evaluation for infertility. American Journal of Epidemiology 1989;129:712‐22. - PubMed
Brinton 2004
    1. Brinton LA, Lamb E, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, et al. Ovarian cancer risk after the use of ovulation stimulating drugs. Obstetrics and Gynaecology 2004;103:1194‐203. - PubMed
Chandra 1998
    1. Chandra A, Stephen EH. Impaired fecundity in the United States: 1982‐1995. Family Planning Perspectives 1998;30:34‐42. - PubMed
Demir 2016
    1. Demir B, Kahyaoglu I, Guvenir A, Yerebasmaz N, Altinbas S, Dilbaz B, et al. Progesterone change in the late follicular phase affects pregnancy rates in both agonist and antagonist protocols in normoresponders: a case‐controlled study in ICSI cycles. Gynecological Endocrinology 2016;32(5):361‐5. - PMC - PubMed
Diergaarde 2014
    1. Diergaarde B, Kurta ML. Use of fertility drugs and risk of ovarian cancer. Current Opinion in Obstetrics & Gynecology 2014;26(3):125‐9. - PMC - PubMed
Duffy 2010
    1. Duffy JMN, Ahmad G, Mohiyiddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3] - DOI - PMC - PubMed
Fathalla 1971
    1. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia?. Lancet 1971;2:163. - PubMed
Finch 2013
    1. Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Hereditary Breast Cancer Study Group. Frequency of premature menopause in women who carry a BRCA 1 or BRCA2 mutation. Fertility and Sterility 2013;99(6):1724‐8. - PubMed
Gates 2010
    1. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histological subtype. American Journal of Epidemiology 2010;171:45‐53. - PMC - PubMed
Greenhall 1990
    1. Greenhall E, Vessey M. The prevalence of subfertility: a review of the current confusion and a report of two new studies. Fertility and Sterility 1990;54:978‐83. - PubMed
Hartge 1989
    1. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ. A case‐control study of epithelial ovarian cancer. American Journal of Obstetrics and Gynecology 1989;161:10‐6. - PubMed
Healy 1994
    1. Healy DL, Trounson AO, Andersen AN. Female infertility: causes and treatment. Lancet 1994;343:1539‐44. - PubMed
Henderson 1998
    1. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer. The Richards and Hinda Rosenthal Foundation Award Lecture. Cancer Research 1988;48:246‐53. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systemic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Homburg 1995
    1. Homburg R, Ostergard H. Clinical applications of growth hormone for ovarian stimulation. Human Reproduction Update 1995;1:264‐75. - PubMed
Karmaus 1999
    1. Karmaus W, Juul S. Infertility and subfecundity in population‐based samples from Denmark, Germany, Italy, Poland and Spain. European Journal of Public Health 1999;9:229‐35.
Kashyap 2004
    1. Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta analysis. Obstetrics and Gynecology 2004;103:785‐94. - PubMed
Langendam 2013
    1. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;23(2):81. - PMC - PubMed
Mahdavi 2006
    1. Mahdavi A, Pejovic T, Nezhat F. Induction of ovulation and ovarian cancer: a critical review of the literature. Fertility and Sterility 2006;85(4):819‐26. - PubMed
Manchanda 2018
    1. Manchanda R, Menon U. Setting the threshold for surgical prevention in women at increased risk of ovarian cancer. International Journal of Gynecological Cancer 2018;28(1):34‐42. - PubMed
McGowan 1979
    1. McGowan L, Parent L, Lednar W, Norris HJ. The woman at risk for developing ovarian cancer. Gynecologic Oncology 1979;7:325‐44. - PubMed
Meader 2014
    1. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82. - PMC - PubMed
Meirow 1996
    1. Meirow D, Schenker JG. The link between female infertility and cancer: epidemiology and possible aetiologies. Human Reproduction 1996;2(1):63‐75. - PubMed
Ness 2002
    1. Ness RB, Cramer DW, Goodman MT. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case‐control studies. American Journal of Epidemiology 2002;155:217‐24. - PubMed
NICE 2013
    1. National Institute for Health and Clinical Excellence (NICE). Fertility: assessment and treatment for people with fertility problems (CG156), 2013. NICE (guidence.nice.org.uk/cg156) (accessed February 2013).
Nugent 1998
    1. Nugent D, Salha O, Balen AH, Rutherford AJ. Ovarian neoplasia and subfertility treatments. British Journal of Obstetrics and Gynaecology 1998;105:584‐91. - PubMed
Pabuccu 2016
    1. Pabuccu EG, Pabuccu R, Evliyaoglu Ozdegirmenci O, Bostanci Durmus A, Keskin M. Combined progesterone (IM+V) versus vaginal progesterone for luteal support in cleavage‐stage embryo transfer cycles of good prognosis patients. Gynecological Endocrinology 2016;32(5):366‐9. - PubMed
Poretsky 1999
    1. Poretsky L, Cataldo NA, Resenwaks Z, Giudice IC. The insulin‐related ovarian regulatory system in health and disease. Endocrine Reviews 1999;20:535‐82. - PubMed
Pozlep 2001
    1. Pozlep B, Meden‐Vrtovec H. Ovulation induction agents and ovarian cancer. Zdravstveni Vestnik 2001;70:525‐9.
Rish 1994
    1. Rish HA, Marrett LD, Hove GR. Parity, contraception, infertility and the risk of epithelial ovarian cancer. American Journal of Epidemiology 1994;140:585‐97. - PubMed
Rish 1998
    1. Rish HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. National Cancer Institute Journal 1998;90:1774‐86. - PubMed
Ron 1987
    1. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology 1987;125:780‐90. - PubMed
Rowe 1993
    1. Rowe PJ, Hargreave TB, Mellows HJ, Comhaire FH. WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. Cambridge, UK: Cambridge University Press, 1993.
Schmidt 1995
    1. Schmidt L, Munster K. Infertility, involuntary infecundity, and the seeking of medical advice in industrialized countries 1970‐1992: a review of concepts, measurements and results. Human Reproduction 1995;10:1407‐18. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Tomao 2014
    1. Tomao F, Lo Russo G, Spinelli P, Stati V, Prete AA, Prinzi N, et al. Fertility drugs, reproductive strategies and ovarian cancer risk. Journal of Ovarian Research 2014;7(51):1‐8. - PMC - PubMed
Van der Linden 2011
    1. Linden M, Buckingham K, Farqhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews 2015;7(7):1‐10. [DOI: 10.1002/14651858] - DOI - PMC - PubMed
Wang 2014
    1. Wang ET, Pisarska MD, Bresee C, Chen YD, Lester J, Afshar Y, et al. BRCA 1 germline mutations may be associated with reduced ovarian reserve. Fertility and Sterility 2014;102(6):1723‐8. - PMC - PubMed
Whittemore 1992a
    1. Whittemore AS. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case‐control studies. American Journal of Epidemiology 1992;136(10):1175‐83. - PubMed
Whittemore 1992b
    1. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case‐control studies. II. Invasive epithelial ovarian cancers in white women. American Journal of Epidemiology 1992;136:1184‐203. - PubMed
Zarchi (a) 2013
    1. Zarchi MK, Rouhi M, Abdolahi AH, Hekmatimoghaddam S. The effect of assisted reproductive technologies on gynecological cancer: report of our experiences and literature review. International Journal of Biomedical Science 2013;9(3):129‐34. - PMC - PubMed
Zhao 2015
    1. Zhao J, Yanping L, Zhang Q, Wang Y. Does ovarian stimulation for IVF increase gynaecological cancer risk? A systematic review and meta‐analysis. Reproductive Biomedicine Online 2015;31:20‐9. - PubMed

References to other published versions of this review

Rizzuto 2010
    1. Rizzuto I, Larsen‐Disney P, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008215] - DOI - PMC - PubMed
Rizzuto 2013
    1. Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD008215.pub2] - DOI - PMC - PubMed

Publication types